These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 12030109

  • 1. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
    Buchmann I, Bunjes D, Kotzerke J, Martin H, Glatting G, Seitz U, Rattat D, Buck A, Döhner H, Reske SN.
    Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
    [Abstract] [Full Text] [Related]

  • 2. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation.
    Reske SN, Bunjes D, Buchmann I, Seitz U, Glatting G, Neumaier B, Kotzerke J, Buck A, Martin H, Döhner H, Bergmann L.
    Eur J Nucl Med; 2001 Jul; 28(7):807-15. PubMed ID: 11504076
    [Abstract] [Full Text] [Related]

  • 3. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
    Kotzerke J, Glatting G, Seitz U, Rentschler M, Neumaier B, Bunjes D, Duncker C, Dohr D, Bergmann L, Reske SN.
    J Nucl Med; 2000 Mar; 41(3):531-7. PubMed ID: 10716329
    [Abstract] [Full Text] [Related]

  • 4. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia.
    Bunjes D.
    Leuk Lymphoma; 2002 Nov; 43(11):2125-31. PubMed ID: 12533037
    [Abstract] [Full Text] [Related]

  • 5. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
    Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, Dohr D, Stefanic M, Buck A, Harsdorf SV, Glatting G, Grimminger W, Karakas T, Munzert G, Döhner H, Bergmann L, Reske SN.
    Blood; 2001 Aug 01; 98(3):565-72. PubMed ID: 11468151
    [Abstract] [Full Text] [Related]

  • 6. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
    Ringhoffer M, Blumstein N, Neumaier B, Glatting G, von Harsdorf S, Buchmann I, Wiesneth M, Kotzerke J, Zenz T, Buck AK, Schauwecker P, Stilgenbauer S, Döhner H, Reske SN, Bunjes D.
    Br J Haematol; 2005 Aug 01; 130(4):604-13. PubMed ID: 16098076
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM.
    J Nucl Med; 1998 Jan 01; 39(1):34-42. PubMed ID: 9443735
    [Abstract] [Full Text] [Related]

  • 8. Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study.
    Zenz T, Glatting G, Schlenk RF, Buchmann I, Döhner H, Reske SN, Bunjes D.
    Haematologica; 2006 Feb 01; 91(2):285-6. PubMed ID: 16461327
    [Abstract] [Full Text] [Related]

  • 9. A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.
    Buchmann I, Kull T, Glatting G, Bunjes D, Hale G, Kotzerke J, Rattat D, Dohner H, Reske SN.
    Eur J Nucl Med Mol Imaging; 2003 May 01; 30(5):667-73. PubMed ID: 12599012
    [Abstract] [Full Text] [Related]

  • 10. Enhanced renal toxicity of total body irradiation combined with radioimmunotherapy.
    Röttinger EM, Bartkowiak D, Bunjes D, Wennauer R, Dohr D.
    Strahlenther Onkol; 2003 Oct 01; 179(10):702-7. PubMed ID: 14566479
    [Abstract] [Full Text] [Related]

  • 11. [Myeloablative radioimmunotherapy with 188Re-CD66mAb before stem cell transplantation. No increase of proinflammatory cytokine levels of TNF-alpha].
    Mutschler J, Steinbach G, Bunjes D, Reske SN, Buchmann I.
    Nuklearmedizin; 2009 Oct 01; 48(1):30-6. PubMed ID: 19212609
    [Abstract] [Full Text] [Related]

  • 12. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation.
    Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Bush SA, Hui TE, Martin PJ, Mitchell D, Press OW.
    Blood; 1995 Feb 15; 85(4):1122-31. PubMed ID: 7849300
    [Abstract] [Full Text] [Related]

  • 13. Dosimetry with (188)Re-labelled monoclonal anti-CD66 antibodies. A simplified approach based on a single measurement 3 h p.i.
    Glatting G, Kull T, Blumstein NM, Bunjes D, Neumaier B, Buck AK, Reske SN.
    Nuklearmedizin; 2006 Feb 15; 45(3):134-8. PubMed ID: 16710510
    [Abstract] [Full Text] [Related]

  • 14. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA.
    J Nucl Med; 2003 Mar 15; 44(3):465-74. PubMed ID: 12621016
    [Abstract] [Full Text] [Related]

  • 15. Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
    Schneider S, Strumpf A, Schetelig J, Wunderlich G, Ehninger G, Kotzerke J, Bornhäuser M.
    Biol Blood Marrow Transplant; 2015 Oct 15; 21(10):1754-60. PubMed ID: 26001695
    [Abstract] [Full Text] [Related]

  • 16. Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.
    Zenz T, Schlenk RF, Glatting G, Neumaier B, Blumstein N, Buchmann I, von Harsdorf S, Ringhoffer M, Wiesneth M, Keller F, Kotzerke J, Röttinger E, Stilgenbauer S, Döhner H, Reske SN, Bunjes D.
    J Nucl Med; 2006 Feb 15; 47(2):278-86. PubMed ID: 16455634
    [Abstract] [Full Text] [Related]

  • 17. 188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation.
    Lauter A, Strumpf A, Platzbecker U, Schetelig J, Wermke M, Radke J, Kiani A, Wunderlich G, Thiede C, Ehninger G, Kotzerke J, Bornhäuser M.
    Br J Haematol; 2010 Mar 15; 148(6):910-7. PubMed ID: 19995390
    [Abstract] [Full Text] [Related]

  • 18. Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation.
    Orchard K, Langford J, Guy M, Lewis G, Michopoulou S, Cooper M, Zvavamwe C, Richardson D, Lewington V.
    Bone Marrow Transplant; 2024 Sep 15; 59(9):1247-1257. PubMed ID: 38867006
    [Abstract] [Full Text] [Related]

  • 19. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.
    J Nucl Med; 2003 Oct 15; 44(10):1690-9. PubMed ID: 14530488
    [Abstract] [Full Text] [Related]

  • 20. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA.
    J Nucl Med; 2000 Dec 15; 41(12):1999-2010. PubMed ID: 11138685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.